Home Antibody All anti-EDA2R antibodies
Also for EDA2R (NM_021783)
|XEDAR antibody was raised against recombinant human XEDAR.|
||WB: 0.5 - 1 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column (Protein A or G Sepharose)
|Homo sapiens ectodysplasin A2 receptor (EDA2R), transcript variant 2|
|EDA-A2R; EDAA2R; TNFRSF27; XEDAR|
|X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2) (1). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappaB and JNK pathways (2). Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis (3). The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment (3).|
Cytokine-cytokine receptor interaction
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of XEDAR in 293 cell lysate with XEDAR antibody at (A) 0.5, (B) 1 and (C) 2 ug/ml.
Immunohistochemistry of XEDAR in human skin tissue with XEDAR antibody at 10 ug/ml.